Ruxolitinib to Combat COVID-19

Summary

The investigators hypothesize that JAK 1/2 inhibition with ruxolitinib, an FDA approved treatment for intermediate or high-risk myelofibrosis, could have a similar effect in patients with severe COVID-19, quelling the immune-hyperactivation, allowing for clearance of the virus and reversal of the disease manifestations.

Timeline

Start

2020-06-30

Primary completion

2021-07-31

Completion

2021-12-31

Outcome

Outcome not reported

Stopped: “Could not make FDA required changes”

Drugs

Indications